JBCHEPHARM (J.B. Chemicals & Pharmaceuticals Ltd.): Acquisition / M&A

Strota Newsroom · session of 2026-07-13 · 13 Jul 18:25 · JBCHEPHARM stock page →

Members of the Exchange are hereby informed that the trading in equity shares of JB Chemicals & Pharmaceuticals Limited… Historically, acquisition / m&a events have moved JBCHEPHARM-type stocks in the bullish direction 48.9% of the next sessions (n=141).

J.B. Chemicals & Pharmaceuticals Ltd. has announced that trading in its equity shares will be suspended from the closing hours of July 16, 2026, due to a Scheme of Amalgamation, according to an NSE filing dated July 13. The company had earlier informed the exchange that the record date for the merger is July 17, 2026. The stock closed at ₹2,460 on July 10, up 1.01% from its previous close of ₹2,435.5.

Events like this—acquisitions and mergers in the Indian market—have historically shown a 48.9% win rate across 141 comparable instances, with a net edge of 0.213%, according to Strota's base rate data. This represents the historical frequency of positive outcomes following such corporate events, not a forecast for this specific transaction.

The stock has gained 2.99% over the past week, 8.11% over one month, and 21.87% over three months, now trading just 1.56% below its 52-week high of ₹2,474. Relative volume stands at 1.3 times average. The RSI-14 reading of 78.9 indicates technically overbought conditions. Valuation metrics show a price-to-earnings ratio of 55.19 and price-to-book of 9.5, with return on equity at 18.7%.

The data establishes that the merger suspension is proceeding on schedule and that the stock has outperformed significantly over the past year with a 49.15% return. It does not establish the final exchange ratio, the post-merger listing timeline, or whether current valuations will be sustained in the combined entity.

The catalyst

Members of the Exchange are hereby informed that the trading in equity shares of JB Chemicals & Pharmaceuticals Limited shall be suspended w.e.f. July 17, 2026 (i.e., closing hours of trading on July 16, 2026) on account of the Scheme of Amalgamation. · NSE

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

JBCHEPHARM right now

trading +1.01% on the day; P/E 55.19; RSI 78.9. Full JBCHEPHARM analysis →

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.